The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The determination and interpretation of the therapeutic index in drug development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Smith, D. A., Di, L., & Kerns, E. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3287 · Cited by 898
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Clozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 462
Lippincott's Illustrated Reviews: Pharmacology
Whalen, K., Finkel, R. S., & Panavelil, T. A. (1991) · Cited by 415
Whitebread, S., Hamon, J., Bojanic, D., & Urban, L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03632-9 · Cited by 404
Eskens, F. A. L. M., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.015 · Cited by 342
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
International Conference on Harmonisation (ICH)
Nahler, G. (2009) · Dictionary of Pharmaceutical Medicine · doi:10.1007/978-3-211-89836-9_719 · Cited by 325
Schnitzer, J. E., & Oh, P. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37571-3 · Cited by 324
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 321
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists
Kvernmo, T., Härtter, S., & Burger, E. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.004 · Cited by 277
Shankar, G., Pendley, C., & Stein, K. E. (2007) · Nature Biotechnology · doi:10.1038/nbt1303 · Cited by 260
In silico prediction of drug toxicity
Dearden, J. C. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1025361621494 · Cited by 259
Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development
Solon, E. G., Schweitzer, A., Stoeckli, M., & Prideaux, B. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9158-4 · Cited by 250
Recognition of Adverse and Nonadverse Effects in Toxicity Studies
Lewis, R. W., Billington, R., Debryune, E., Gamer, A., Lang, B., & Carpanini, F. (2002) · Toxicologic Pathology · doi:10.1080/01926230252824725 · Cited by 246
Drug Safety Sciences and the Bottleneck in Drug Development
Watkins, P. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.63 · Cited by 211
Harmer, A., Valentin, J.-P., & Pollard, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01415.x · Cited by 158
Native albumin for targeted drug delivery
Neumann, E., Frei, E., Funk, D., Becker, M. D., Schrenk, H., Müller‐Ladner, U., & Fiehn, C. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.498474 · Cited by 147
Muller, P. Y., Milton, M., Lloyd, P. M., Sims, J., & Brennan, F. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.013 · Cited by 146
Self-citationUse of Transcriptomics in Understanding Mechanisms of Drug-Induced Toxicity
Cui, Y., & Paules, R. S. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.37 · Cited by 133
Muller, P., & Brennan, F. R. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.273 · Cited by 107
Self-citationCardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani, E. Z., & Islam, K. (2008) · PubMed · Cited by 101
Fuchs, H., Tillement, J. P., Urien, S., Greischel, A., & Roth, W. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.01.0008 · Cited by 93
In silicomodels for drug-induced liver injury – current status
Przybylak, K. R., & Cronin, M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.648613 · Cited by 82
Mano, Y., Usui, T., & Kamimura, H. (2006) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.527 · Cited by 81
Imatinib mesylate for the treatment of pulmonary arterial hypertension
ten Freyhaus, H., Dumitrescu, D., Berghausen, E. M., Vantler, M., Caglayan, E., & Rosenkranz, S. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.632408 · Cited by 65
Lee, C., Zhu, C., Malysz, J., Campbell, T., Shaughnessy, T. K., Honoré, P., Polakowski, J. S., & Gopalakrishnan, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.044 · Cited by 64
Muller, P. Y., & Dieterle, F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903114174 · Cited by 62
Self-citationProteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity
Summeren, A. V., Renes, J., van Delft, J. H. M., Kleinjans, J. C. S., & Mariman, E. C. M. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.01.012 · Cited by 53
In Vitro Safety Pharmacology Profiling: What Else Beyond Herg?
Hamon, J., Whitebread, S., Techer-Etienne, V., Coq, H. L., Azzaoui, K., & Urbán, L. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.51 · Cited by 50
Toutain, P., & Lefebvre, H. (2004) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00601.x · Cited by 46
Genomic and proteomic approaches for predicting toxicity and adverse drug reactions
Ge, F., & He, Q. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802661895 · Cited by 26
Comparative requirements for exploratory clinical trials — eIND, eCTA and microdosing
Muller, P. Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.010 · Cited by 14
Self-citation
Cited by
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Metadata
- Authors
- Muller, P. Y., & Milton, M. N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-08-31
- Volume
- 11
- Issue
- 10
- Pages
- 751-761
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1965665318
- Cited by
- 563
- References
- 38
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.